Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?

Autores de IIS La Fe

• Gladys Guadalupe Olivera Pasquini

  Autor

• Andrea Urtasun Erburu

  Autor

• Luis Sendra Gisbert

  Autor

• Salvador F Aliño Pellicer

  Autor

• Yania Yañez Peralta

  Autor

• Vanessa Segura Caballer

  Autor

• Pablo Gargallo Tatay

  Autor

• Victoria Castel Sánchez

  Autor

• Adela Cañete Nieto

  Autor

• María José Herrero Cervera

  Autor

Participantes ajenos a IIS La Fe

• Berlanga, P

Grupos

• Farmacogenética

• Investigación Clínica y Traslacional en Cáncer

Abstract

Pharmacogenetics is one of the cornerstones of Personalized Precision Medicine that needs to be implemented in the routine of our patients' clinical management in order to tailor their therapies as much as possible, with the aim of maximizing efficacy and minimizing toxicity. This is of great importance, especially in pediatric cancer and even more in complex malignancies such as neuroblastoma, where the rates of therapeutic success are still below those of many other types of tumors. The studies are mainly focused on germline genetic variants and in the present review, state of the art is presented: which are the variants that have a level of evidence high enough to be implemented in the clinic, and how to distinguish them from the ones that still need validation to confirm their utility. Further aspects as relevant characteristics regarding ontogeny and future directions in the research will also be discussed.

Keywords

• SNP (single nucleotide polymorphism); chemotherapy; drug label; clinical implementation guidelines